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Mast cell degranulation breaks peripheral tolerance
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Abstract
Mast cells (MC) have been shown to mediate regulatory T-cell (Treg) dependent, peripheral
allograft tolerance in both skin and cardiac transplants. Furthermore, Treg have been implicated in
mitigating IgE mediated MC degranulation, establishing a dynamic, reciprocal relationship
between MC and Treg in controlling inflammation. In an allograft tolerance model, it is now
shown that intragraft or systemic MC degranulation results in the transient loss of Treg suppressor
activities with the acute, T-cell dependent rejection of established, tolerant allografts. Upon
degranulation, MC mediators can be found in the skin, Treg rapidly leave the graft, MC
accumulate in the regional lymph node and the Treg are impaired in the expression of suppressor
molecules. Such a dramatic reversal of Treg function and tissue distribution by MC degranulation
underscores how allergy may causes the transient breakdown of peripheral tolerance and episodes
of acute T-cell inflammation.
Introduction
Mast cells (MC) are best known for their role in allergies and protecting our body from
parasitic, bacterial and viral infection(1). IgE antibody against the allergen or infectious
agent binds to the high affinity IgE receptor on MC. Subsequent encounter with allergen
leads to release of the MC granular content with heightened inflammation. While the
historical role of MC has been as regulators of inflammatory responses, MC have been
recently been implicated as regulators of tolerance(2, 3). The striking contrast in MC
function is exemplified by their pro-inflammatory roles in nematode infection and
allergies(1) or their role in mediating suppression, as in UV-B damage(4), mosquito bites(5)
and graft tolerance(6, 7). Recently, the pivotal role of MC in the establishment of acquired
tolerance to an allograft was shown(6, 7). It was hypothesized that the secretion of
immunosuppressive mediators by MC was critical for sustaining tolerance.
Recently, the dynamic and reciprocal nature of MC-Treg interactions was shown. It was
reported that Treg can suppress IgE mediated degranulation through OX40-OX40L
interactions(8, 9) thereby showing a natural mechanism for MC stabilization. It is clear that
the release of inflammatory mediators as a consequence of MC degranulation results in
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inflammation. How this impacts peripheral tolerance and Treg function is not known.
Therefore, studies were designed to determine if degranulation of MC present in tolerant
allografts would impact on allograft survival. Data presented show that IgE-mediated
degranulation, either within the graft or systemically, breaks established peripheral tolerance
and leads to T-cell mediated, acute rejection of the allograft. Degranulation causes release of
MC intermediaries, a rapid migration of both Treg and MC from the graft as well as a
transient demise in the expression of Treg suppressive cytokines. Such a dramatic reversal of
Treg function and tissue distribution by MC degranulation underscores how allergy may
cause the transient breakdown of peripheral tolerance and episodes of acute T-cell
inflammation.
Material and methods
Mice
C57Bl/6, CB6F1 (C57Bl/6xBALB/c hybrid), C57BL/6-Ly5.2+, and C57BL/6-Rag-/- mice
were purchased from the Jackson Laboratory. FoxP3/GFP reporter mice were provided by
Dr. A. Rudensky (University of Washington School of Medicine, Seattle, WA)(23).
Skin graft model
Skin grafting was performed described previously(43). For dual grafting, the first graft was
placed on the back near the base of the tail, whereas the second graft was placed on the back
close to the neck two weeks later. Grafts were monitored for rejection for 30 days post-
degranulation and were considered rejected when 80% of the original graft disappeared or
became necrotic.
Degranulation
Chemical degranulation was done by application of 50μl Compound 40/80 (1mg/ml, Sigma)
directly under the graft. “Active” immunization was achieved by 100μg of OVA/Alum
(Pierce) i.p., 37 days prior to grafting or passive by transfer of IgE. For passive
immunization 2 or 5μg of either OVA-specific IgE (clone 2C6; Serotec) or TNP-specific
IgE (clone A3B1; cross-reactive with NP) was given intravenously 24h prior to
degranulation, respectively. Degranulation was induced either locally (50μl of 1mg/ml OVA
in PBS) or systemically (500μl of 1mg/ml OVA in PBS intraperitoneal) for mice that
received OVA-IgE or were active immunized. Degranulation in mice that received NP-IgE
was done by injecting 20ng of NP17-OVA/NP23-BSA locally. Blocking of degranulation
was done by subcutaneous injection of 100μl of Cromolyn Sodium Salt (39mM in PBS,
Sigma-Aldrich) 30 minutes prior to degranulation.
Cytokine profile of the graft
Grafts were collected, cut to small pieces in HBSS (6 grafts/ml) 18h post-degranulation and
incubated for 1h at 37°C. Cytokines in the supernatants were determined by multiplex
analysis(Biorad) and verified by ELISAs (IL4, IL6, IL10(Pharmingen), IL9(PeproTech) and
TNFα(eBioscience)).
Induction of inflammation
Mice were either treated with 200μl complete Freund's adjuvant (Sigma), 50μg TLR4
agonist (LPS, E. coli 055:B5, Sigma) or 50μg TLR9 agonist (CpG; ODN-1826,
Eurogentech) by intraperitoneal injection. For induction of local inflammation 8μl of 5mg/
ml FITC(Sigma) in 1:1 acetone(Fisher scientific)/dibutylphthalate(Sigma) was applied
directly onto the pre-shaved graft. Positive controls included degranulation after passive
immunization or intraperitoneal injection of 50μg of agonistic αCD40 (FGK; BioExpress).
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Immunohistochemistry
Tissues were snap-frozen and 8μm sections were fixed with methanol prior to staining with
α-CD117-A647. Hoechst was used for nuclear staining. Slides were analyzed by confocal
microscope (LSM510Meta, Zeiss) at a 100× magnification. To analyze granulated MC,
slides were stained with toluidine blue(Sigma). Toluidine blue-positive MC numbers in skin
were determined by counting the number of stained MC in seven randomly chosen fields at
100x magnification by two independent observers using an Olympus DP70 camera system
operating on a BX60 transmitted microscope.
Cell isolation and analysis
Naïve T-cells were isolated from pooled spleen and LN. Prior to cell sorting, T-cells were
pre-enriched by CD4 negative selection (biotin-selection kit, Stemcell). Isolation of graft T-
cells from FoxP3-GFP mice was performed by digestion with DNAse, Liberase and
Collagenase (10mg/ml, Roche) for 45 minutes at 37°C after weighing the grafts. Analysis
was performed after co-staining with CD4(RM4-5, Pharmingen) by flow-cytometry. For
determination of the total number of MC in the dLN, samples were stained with
CD117(clone: 2B8) and FcεRI(MAR-1, eBioscience) and analyzed by flow-cytometry.
T-cell studies in vivo
At day 27 and 35 mice were treated with 300μl intraperitoneal and 50μl locally at the site of
the graft with mixture of αCD4(GK1.5) and αCD8(2.43) antibodies (kind gift from Dr. MJ
Turk, Dartmouth, NH, USA) to deplete T-cells. Depletion was confirmed at day 37. For the
transfer of tolerance experiments, grafts dLN were collected at day 35 and T-cells purified
by two rounds of CD4 negative depletion(StemCell). RAG-/- received an F1 graft two weeks
prior to adoptive transfer of 1×106 purified T-cells by i.v. injection.
Functionality of regulatory T-cells in vitro and in vivo
One day post-degranulation FoxP3-GFP+ T-cells from the graft dLN were FACS sorted. For
in vitro studies, Ly5.2+ naïve T-cells were purified by FACS sorting and labeled with
carboxyfluorescein succinimidyl ester (5μM, CFSE). In total 5×104 were cultured with T-
depleted irradiated Ly5.1+ splenocytes (3000rad) at different ratios of Treg:Tnaïve. After 3
days CFSE dilution, profiles were analyzed within the Ly5.2+ population. For in vivo
functionality, GFP+/Ly5.1+ Treg were mixed at different ratios naïve, polyclonal T-cells and
adoptively transferred into F1 pregrafted RAG-/-. Phenotypic analysis of Treg was
performed by staining T-cells of the dLN after CD4 enrichment. All samples were stained
with FoxP3 in either FITC or PE depending on the co-staining. FoxP3+ cells were analyzed
for the expression of Ki67 (Ki67 staining kit, BD), CTLA4(UC10-4F10-11, Pharmingen),
ICOS(15F9, eBioscience), CD62L(MEL-14, BioLegend), CD73(clone TY/11.8,
eBioscience), CD103(2E7, eBioscience), GITR(YGITR 765, BioLegend), IL7Rα(CD127;
A7R34, eBioscience). For RT-PCR analysis FoxP3+ Treg from the grafted FoxP3-GFP
mouse were flow sorted. The primers used for estimates of gene expression were: TGF-β1
forward: 5′-ttgcttcagctccacagaga-3′, TGF-β1 reverse: 5′-tggttgtagagggcaaggac-3′, IL-10
forward: 5′-ggttgccaagccttatcgga-3′, IL-10 reverse: 5′-acctgctccactgccttgct-3′, Ebi3 forward:
5′-AGCAGCAGCCTCCTAGCCT-3′, Ebi3 reverse: 5′-gcggagtcggtacttgagag-3′, granzymeB
forward: 5′-ctccacgtgctttcaccaaa-3′, granzymeB reverse: 5′-aggatccatgttgcttctgtagttag-3′.
Statistics
All statistics have been calculated using the prism 4.03 software package (GraphPad
Software, San Diego California USA). Survival data were analyzed using the Kaplan-Meier
method, with the Wilcoxon rank test and the log-rank test. Luminex data were analyzed by
the immune monitoring laboratory of the Norris Cotton Cancer Center/Dartmouth Hitchcock
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Medical Center and are shown as mean +/- SD whereas other data are expressed as mean +/-
SEM. The latter were analyzed by one-tailed ANOVA and post-tested by Tukey analysis.
Statistical significance was calculated for a 95% confidence interval (P<0.05). The exact p-
values are denoted in the figures.
Results
MC degranulation results in the rejection of an established tolerant allograft
Previously we showed that in mice tolerized with αCD154 and donor specific transfusion
(DST) both Treg and MC accumulate in the tolerant allograft and are functionally critical for
allograft persistence(7). Herein, it was asked if IgE-mediated MC degranulation and the
release of inflammatory mediators would alter Treg function, distribution and impact on
allograft persistent in the tolerant host.
Both tolerized and syngeneic control mice were treated as shown in figure 1A, unless stated
differently(10-12). Within 15 days, all tolerized mice bearing an allogeneic skin graft in
which MCs had been degranulated lost their grafts. Syngeneic mice maintained their grafts
for the duration of the experiment regardless of treatment(Fig.1B). These results indicate
that degranulation of MC facilitates the rejection of allogeneic skin grafts in tolerized hosts.
Both active immunization with OVA-Alum 30 days prior to grafting, followed by challenge
with OVA as well as chemically induced (compound 40/80)(13, 14) degranulation showed
the same results as with passive immunization(Supplementary fig.1A and 1B, respectively).
Cytokines known to be abundant after IgE mediated MC degranulation were increased in
groups where MCs had been degranulated(Fig.1C), confirming that the MC released their
granular content and established a pro-inflammatory Th2-biased micro-environment similar
to that observed in allergies(15).
Comparison of different inflammatory mediators in inducing graft rejection of tolerant
allografts
A battery of inflammatory mediators was used to evaluate if any inflammatory insult under
tolerizing conditions would inevitably lead to graft rejection. Mice were treated with
inflammatory doses of the Toll-like receptor (TLR) 4 agonist, LPS; the TLR9 agonist, CpG-
ODN 1826; Complete Freund's Adjuvant (CFA) or an agonistic αCD40 antibody. Finally,
local, chemical-induced Th2-biased inflammation was induced using acetone/
dibutylphthalate/FITC applied directly onto the graft(16-18). No acute rejection was
observed in any of the groups tested except for the tolerant mice administered αCD40
antibody, as previously reported(19). These data demonstrate that the acute rejection
observed after degranulation was not due to the introduction of overt inflammation per
se(Fig.1D) but due to the nature of the inflammatory microenvironment created by
degranulation.
Mast cell stabilization leads to prolonged allograft survival
To seek further evidence that breakdown of allograft tolerance was the effect of MC
degranulation, degranulation was blocked by local intragraft injection of sodium
cromoglycate (cromolyn)(20). The observed acute rejection after MC degranulation was
completely blocked with the administration of cromolyn(Fig.2A) thereby confirming that the
acute allograft rejection was the result of degranulation.
In this system of allograft tolerance, peripheral tolerance begins to decay at day 70 post-
grafting in tolerant mice(21). To address if limited allograft survival in tolerized mice was
due to “low-grade” MC degranulation, cromolyn was applied to the allograft at day 30 and/
or day 60 after engraftment. Single treatment did not impact graft survival. However, when
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performed on both days, allografts were maintained for >120 days even when allergic
exacerbations were mimicked right after cromolyn treatment(Fig.2B). These results show
that allograft survival in tolerized mice can be extended by the administration of cromolyn,
and suggests that MC degranulation may contribute to the natural decay of tolerance in this
system.
MC degranulation leads to an accumulation of MC in the draining lymph nodes
To define the cellular events occurring upon MC degranulation, tolerant and syngeneic skin
grafts were collected at day 1 and 5 after degranulation. Degranulation leads to
disappearance of MC from the allograft, as measured with by the number of c-Kit+ cells
present within the graft(Fig.3A) and inversely correlated with the number of MC in the
corresponding allograft-draining axillary and brachial LN as quantified by the number of c-
KithighFcεRIhigh cells(Fig.3B). MC numbers were confirmed by toluidine blue staining of
both graft and dLN(Supplementary fig.2). Taken together, these data suggest that upon
degranulation, some MC degranulate and other MCs egress from the skin and enter the
draining lymph.
MC degranulation-mediated rejection is dependent on T-cells
In order to address whether the rejection observed after MC degranulation was dependent
upon T-cells, CD4+ and CD8+ T-cells were eliminated with depleting antibodies. MC
degranulation in the absence of T-cells did not lead to graft loss(Fig.4A). Similar results
were obtained using compound 40/80 to degranulate the MC(Supplementary fig.3). This
demonstrates that T-cells were mediating graft rejection after degranulation.
MC degranulation results in a breakdown of T-cell tolerance
It is known that in this system a balance of allogeneic effector T-cells (Teff) and Treg
controls graft rejection, and suggests that MC degranulation has an impact on this balance.
To directly measure the intrinsic ability of T-cells from tolerant mice to mediate graft
rejection or not, an adoptive transfer study was designed. Purified dLN T-cells from the
different groups were transferred into RAG-/- mice bearing an allograft. Adoptive transfer of
CD4+ T-cells from tolerized mice after local MC degranulation rejected the allografts in the
secondary recipients(fig.4B). These data show that MC degranulation restores alloreactive
T-cell responses in a tolerized mouse.
Regional degranulation results in the systemic decay of peripheral tolerance
Studies were designed to address whether local MC degranulation would facilitate a
breakdown in allograft tolerance at the systemic level. To test this, tolerized mice received
two skin allografts, one at day 0 and one at day 14. The first allograft (graft #1) was draining
into the inguinal lymph nodes. The second graft (graft #2) drained to the brachial and
axillary lymph nodes (day14)(22). At day 30 graft #1 was challenged after passive
immunization and rejected at the expected kinetics. Interestingly, graft #2 was also rejected
after a delay of about 1-2 days(Fig. 4C). As a control to ensure local degranulation of graft
#1, a cohort of mice received a syngeneic graft #1 and an allogeneic graft #2. Local
degranulation of the syngeneic graft did not lead to rejection of the allogeneic graft
confirming allergen was not reaching the other graft. Together, these data demonstrate that
local MC degranulation leads to a systemic breakdown of peripheral tolerance.
Degranulation facilitates Treg and MC loss from the graft and impairs Treg function
MCs and Treg are present in tolerant allografts and are required to maintain allograft
tolerance(7). It was hypothesized that degranulation may change Treg composition and
functionality, thereby altering graft longevity. Following degranulation, Treg were
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enumerated in the grafts by using Foxp3-GFP mice(23) as hosts. At day 1 following MC
degranulation, a dramatic reduction of CD4+Foxp3+ was observed in allografts(Fig.5A). At
this time point, MCs were still present in the allograft(Fig.3A), demonstrating that the efflux
of Treg precedes the efflux of MC from the skin allograft following MC degranulation.
In addition to the altered distribution of Treg, the in vitro and in vivo functions of Treg were
also evaluated following MC degranulation. Treg function was measured in vitro by a
suppressor assay. Treg from both tolerized, allografted mice and from those bearing
syngeneic grafts suppressed WT Teff proliferation, as measured by CFSE dye dilution.
However, Treg from mice whose MC were degranulated 1 day prior, were less effective at
suppressing Teff proliferation(Fig.5B). The impairment in Treg suppression was transient,
because Treg harvested at day 5 post-degranulation, regained their ability to suppress Teff
indistinguishably from the non-degranulated controls. These results indicate that MC
degranulation leads to a transient reduction in Treg function. Furthermore, Treg function was
also impaired after MCs were degranulated in mice bearing syngeneic grafts, suggesting this
is a general mechanism of immune regulation mediated by MC. Of note, Teff in the same
groups as tested in Fig.5B could still be suppressed by WT-Treg(data not shown).
To examine whether Treg after MC degranulation are impaired in vivo, an in vivo Treg
suppressor assay was performed. Treg were mixed with WT-Teff and adoptively transferred
into pre-grafted RAG-/- mice. The majority of mice which received Treg from non-
degranulated mice at a 1:10 Teff:Treg ratio, retained their allogeneic grafts for the duration of
experiment. However, grafts were rejected when Treg were isolated after MC degranulation
at the same ratio of Teff:Treg(Fig.5C). In sum, these data indicate that after MC
degranulation, Treg transiently lose their ability to mediate graft survival.
MC degranulation leads to a reduced expression of key Treg immunomodulatory molecules
To define the underlying molecular mechanisms for the loss in Treg function after
degranulation, the expression of key surface molecules and cytokines was analyzed.
Comparative FACS analysis revealed no changes in the expression of markers involved in
maturation/migration (CD62L, CD103), peripheral homeostasis (IL7αR), proliferation
(Ki67) and contact dependent suppression (CTLA4, ICOS, CD73, GITR). Additionally, the
level of FoxP3 expression was not changed as shown by histogram overlay and bar diagram
of the MFI for the individual conditions(Fig.6A). Together, these results indicate that the
prominent Treg markers noted are not affected by MC degranulation.
The expression of suppressive mediators molecules (TGFβ, IL10, Granzyme B(GzB) and
EBI3 (Ebstein Bar virus Induced gene 3)) secreted by FACS-purified FoxP3-GFP Treg were
determined by RT-PCR. TGFβ mRNA expression was reduced over 50% in Treg harvested
24 hours after MC degranulation but was restored at day 5 post-degranulation when
compared to Treg from non-degranulated controls. The mRNA levels of IL10 and GZB were
nearly absent at 24 hours post-degranulation, with a modest recovery of expression for IL10
at 5 days post-degranulation. EBI3, however, was not impacted by MC degranulation at 24
hours post-challenge yet declined at day 5(Fig.6B). Taken together, these data suggest that
MC degranulation leads to the loss of multiple suppressive mediators utilized by Treg which
may account for the loss in peripheral tolerance upon degranulation.
Discussion
The studies presented significantly advance our knowledge of MC-Treg interactions and how
degranulation impacts on the behavior and function of Treg. The data show 1) that antibody
or chemically-induced MC degranulation, either regionally or systemically leads to a T-cell-
dependent loss of tolerant skin allografts, 2) the “natural” loss of tolerant allografts can be
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reversed by the blockade of MC degranulation in vivo, 3) degranulation of MC causes a
rapid change in the cellular composition of the tolerant microenvironment, with a loss in
both MC and Treg, 4) regional degranulation ultimately results in systemic breakdown in T-
cell tolerance, 5) MC degranulation causes a transient loss in Treg function.
Prior studies have documented the persistence of MC in tolerant allografts and their
functional involvement in allograft survival. Histological examination indicated that these
intragraft MC were not degranulated(6, 7). Based on these observations, it was suggested
that the secretion of immunosuppressive mediators by MC was critical for maintaining the
allograft(6, 7). In light of these findings, the impact of MC degranulation on the delicate
balance of Treg and Teff under tolerant conditions was investigated. The various methods
used for degranulation all led to acute T-cell-dependent allograft rejection.
MC-mediated graft loss could be blocked by using the MC stabilizing agent cromolyn
providing additional proof that degranulation imparts an immunostimulatory impact leading
to a breakdown in tolerance. Cromolyn has been effectively and safely used for over 30
years as a prophylactic treatment in allergies(24). A recent retrospective study demonstrated
that blocking MC degranulation by a single application of cromolyn is effective in
preventing allergies later in life. Most likely a permanent change in the composition of T-
cell compartment was induced by the brief stabilization of the MC(25). Also preservation of
transplant organs is prolonged by cromolyn by protecting the tissues from ex vivo, MC
mediated, ischemia(26, 27). In the study presented, while a single application of cromolyn
did not impact graft survival, a sequential treatment on day 30 and 60 post-engraftment
prolonged allograft tolerance over 120 days. We suspect that in the absence of MC
stabilization erosion of allograft tolerance over time as seen in this model could be partially
explained by low levels of MC degranulation occurring even in the absence of allergens.
The regional or systemic delivery of allergen results in the tempered degranulation of MC
with a significant proportion of MC retaining their granule content. MC degranulation
resulted in the sequential egress of Treg and MC from the allograft. Unresolved is the role of
MC graft egress and putative LN accumulation to the process of graft rejection. However,
the lack of complete degranulation of the MC upon administration of allergen may be the
result of the immunosuppressive impact that Treg exert on MC degranulation. Recent
evidence has shown that Treg, can suppress MC degranulation by contact dependent OX40-
OX40L interactions as well as by a contact independent manner through IL10 secretion in
vitro(28, 29, 8). However, even in the absence of Treg, MC degranulation is likely never
complete since only a 50% reduction of granulated MC has been reported after C40/80
treatment(30).
It has been previously reported that the adoptive transfer of Treg from untreated animals can
suppress ongoing allergy(32, 33). This observation suggests a functional defect in the Treg
compartment during allergy. No phenotypic differences were observed and the level of
FoxP3 expression was similar at all analyzed time points. This is in contrast to a recent
report that during rejection levels of FoxP3 of Treg are downregulated(34). Either this could
be induced by using a different transplant model or degranulation leads to a different type of
rejection as normal allograft rejection based on minor histocompatibility differences. Both in
vitro and in vivo analyses revealed a temporary impaired ability of the Treg to suppress Teff
responses after degranulation. This suggests a regulatory role for MC in Treg functionality.
The underlying cause for the loss of Treg suppression may be due to the loss of expression of
GZB as well as TGFβ, and/or IL10. Many studies have examined the function of Treg in
atopic patients, but the findings from these studies are inconclusive(34-39). Some of the
discrepancies from these studies can be explained, however, by the observation herein that
de Vries et al. Page 7
Am J Transplant. Author manuscript; available in PMC 2013 October 28.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
there is only a brief window of time where the Treg lose their suppressive function after
degranulation.
The findings over the past 5 years underscore the enormous plasticity of the MC
compartment and their impact on acquired immunity and acquired immune privilege(40).
While MC have been extensively described in type I hypersensitivity diseases as being pro-
inflammatory, it is evident that MC control the development and persistence of peripheral
tolerance and immunity(6, 7). Unlike T-cells, which can be decisively segregated into
multiple effector and regulatory subsets, there are no defined subsets of functionally diverse
MC(2). Emerging studies implicate MC as accessory cells for both Teff and Treg alike to
mediate inflammation and suppression, respectively. The findings of this study are the first
to show the reciprocal impact of MC degranulation on Treg function. The implications in
allergy and in peripheral tolerance are significant. The clinical relevance for the presented
data in regards to allograft transplant recipients becomes evident when the data from a
retrospective study in patients who received a kidney transplant is taken into consideration.
Atopic individuals, in this case allergic rhinitis, with a kidney transplant show more severe
and acute episodes of rejection then individuals without any history of allergy(41). These
data are concordant with our observation that MC degranulation breaks peripheral tolerance
systemically.
In closing, with the increasing prevalence of allergies in Western countries,(42) the
durability of allografts in atopic patients may suffer increasing jeopardy. Long term MC
stabilization in transplant recipients could be beneficial in maintaining intact MC and
functional Treg at the site of the graft and preventing temporal impairment of suppression
due to degranulation. Since the regulation of Treg function seems to be a one component of
MC function, defining MC products leading to down regulation of suppressive pathways in
Treg will be a great asset for developing new treatment strategies in a variety of diseases
where either loss of suppression needs to be restored or ablated. Altogether, MC seem to be
able to regulate the immune response in general and Treg function in particular, either by
supporting tolerance via secretion or by inducing inflammation via degranulation.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Degranulation of mast cell leads to acute rejection of established tolerant skin grafts
A. To induce tolerance, C57BL/6 mice were administered a regimen of donor specific
transfusion (DST) of allogeneic splenocytes and anti-CD154 (200μg i.p.). Subsequently,
mice received an allogeneic skin graft and survival was monitored. These mice maintain the
graft for up to 100 days post-grafting, with day 0 designated as the day the mice received the
graft. MCs were degranulated in mice 30 days after engraftment receiving the tolerance-
inducing regiment and an allograft, in all studies described. At day 0 mice received either an
CB6F1 graft (designated tolerant/tol) or a syngeneic (syn) B6 graft. Syngeneic and rejecting
mice did not receive pretreatment. At day 29 mice were sensitized with 5μg of NP specific
IgE (NP-IgE) and 24 hours later challenged with NP17-OVA or NP23-BSA, systemically
(20ng/mouse intraperitoneal) or locally (2ng/mouse intragraft). Graft rejection was
monitored for another 30 days. B. Survival of grafts for both systemic and local treatment.
Controls included were either sensitized with PBS followed by local challenge with NP17-
OVA or sensitized with NP-IgE followed by local challenge with 20ng of OVA. The total
number of mice pooled from multiple independent experiments is shown in brackets. C.
Tolerant and syngeneic with and without degranulation were collected 18 hours after
degranulation and incubated in HBSS for 1h at 37°C. Supernatants were collected and tested
for functionality in a proliferation assay (data not shown). Cytokine analysis was performed
by multiplex and results were confirmed by ELISA. Shown are chemokines and cytokines
known to be abundantly present under allergic conditions(15). D. In order to see whether
degranulation induced rejection was solely the effect of inflammation various strategies
were used to induce overt inflammatory responses. Mice were treated with 50μg TLR4 or
TLR9 agonist, 200μl CFA or local by chemically induced inflammation. As positive
controls agonistic CD40 and degranulation were included. Data shown is combined from
two independent experiments.
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Figure 2. Mast cell stabilization protects against degranulation induced rejection and prolongs
graft survival in general
A. Mice were treated according figure 1A. However, 30 minutes prior to local challenge
with 20ng of NP17-OVA one group received an intragraft injection of 100μl of a 39mM
solution of cromolyn, a chemical known to stabilize MC thus preventing degranulation. The
total number of mice pooled from three independent experiments is shown in brackets. B.
Passively immunized mice were treated locally with Cromolyn at day 30 and/or day 60 post-
grafting either with or without local degranulation. Grafts were monitored for a total of 120
days. The number of mice in each group, as shown in brackets is from multiple independent
experiments. For both figure A and B the relevant syngeneic controls for this experiment did
not show rejection for the entire duration of the experiments and are omitted from this figure
for clarity.
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Figure 3. Local IgE mediated degranulation leads to migration of MC from the graft to the
draining LN
A. Grafts were degranulated locally after passive immunization. Confocal images of
representative tolerant and syngeneic grafts with MC (cKit+FcεRI+) shown in green. Nuclear
stain with Hoegst are shown in blue. Quantification of the number of MC in the skin was
performed by counting 7 randomly chosen fields in a total of 6 individual mice. B.
Flowcytometric analysis of the draining, pooled inguinal and axillary, lymph nodes. After
digestion with DNAse/liberase single cell suspensions were counted and stained with cKit
and FcεRI. A representative plot is showing MC in the gate after pre-enrichment with FcεRI-
PE on the left. Cell counts were performed before and after enrichment to calculate the
absolute number of MC (cKithighFcεRIhigh) in the dLN as shown on the right. Data is
combined from 3 independent experiments with a total of 9 mice.
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Figure 4. Break of peripheral tolerance by degranulation is T-cell dependent
A. Graft survival after depletion of CD4 and CD8 T-cells with αCD4 and αCD8 antibodies
(300μl intraperitoneal and 50μl local) 2 days prior to and 5 days after local degranulation at
day 30. Grafts were monitored for another 30 days after degranulation and the data shown is
pooled from two independent experiments. B. RAG-/- were grafted 2 weeks prior to adoptive
transfer of 1.106 lymphocytes from the inguinal and axilliary draining LN of the indicated
groups. One day after degranulation lymph nodes were isolated and T-cells were purified by
two rounds of negative depletion yielded over 92% purity. Graft survival measurement starts
at the day of transfer of lymphocytes. Pooled data is shown from in total 3 independent
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experiments. C. In order to see whether degranulation could lead to rejection of a graft in a
distant location, mice received two graft two weeks apart. The first graft was placed close to
the base of the tail and the second graft was in the neck to assure both grafts drained to
separate lymph nodes. All mice receiving an allogeneic CB6F1 graft were pretreated with
DST/αCD154. At day 29 mice with two accepted grafts were included in the study. After
passive immunization the first graft was locally challenged. Graft survival of a secondary
graft was monitored for another 30 days. In order to control for aspecific rejection due to
antigen drainage to the second graft a control was included where the first graft was
syngeneic, and thus would not reject by degranulation, and the second graft was a allogeneic
CB6F1 graft. Treatment and source of the first graft is indicated in between squared
brackets. Data is combined from multiple experiments and the total number of mice used is
shown in round brackets.
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Figure 5. Mast cell degranulation leads to efflux of Treg from the graft and a transient block in
regulatory T-cell function
A. Quantification of CD4+FoxP3+ T-cells (Treg) in the grafts of tolerized and syngeneic
mice with and without local degranulation after passive immunization. Grafts were collected
and individually weighted before digestion with DNAse/Dispase/Collagenase. Single cell
suspension were counted and stained with CD4 before analysis by flowcytometry. Total
number of Treg/mg graft tissue is shown for a total of 6 mice from 2 independent
experiments. B. Following degranulation of tolerized, allografted mice, Ly-5.2+ Treg were
harvested from the dLNs of Foxp3-GFP mice and FACS-purified based on GFP expression
at day 1 or day 5 after local degranulationto be used in a standard suppressor assay. Briefly,
naïve CD4 T-cells from wildtype, C57Bl/6 mice (Teff cells), expressing Ly5.1 were purified
and labeled with CFSE. FACS-purified Ly5.2 Treg based from either degranulated or non-
degranulated hosts were mixed at different ratios with Teff cells, and Treg dependent
suppression was measured by CFSE dye dilution. Grafting of mice was staggered in order to
be able to isolate the Treg on the same day. Cells were flow sorted and mixed with
congenically (Ly5.2+) marked CFSE labeled naïve polyclonal T-cells at the indicated ratios.
After 4 days of culture the Ly5.2+ cells were analyzed for CFSE dye dilution. Shown are
representative histograms of multiple independent experiments. C. Treg were purified from
tolerized, allografted FoxP3+-GFP mice which were untreated or degranulated with allergen.
As in figure 5B, 24 hours after degranulation, Treg from tolerized controls or degranulated,
tolerized groups were FACS purified based on GFP expression. Treg from each of these
groups were mixed at ratios with WT, Teff (Teff: Treg) to be used in an in vivo suppressor
assay. RAG-/- mice were grafted 2 weeks prior to adoptive transfer of in total 1.106
lymphocytes. Grafts were monitored for rejection for 60 after transfer of the T-cells. Data is
pooled from 3 independent experiments with the total number of mice shown in brackets.
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Figure 6. Degranulation blocks transcription of multiple important mediators used by Treg for
suppression
A. Phenotypic analysis of Treg isolated from the draining lymph nodes of treated and
control mice by flowcytometry. T-cells were isolated from the draining, brachial and
axillary, lymph nodes of the graft at day 1 and day 5 after degranulation and grafting was
staggered in order to analyze all sample on the same day. Single cell suspensions were
stained with CD4 and FoxP3 in combination with the shown markers. Histograms shown are
from CD4+/FoxP3+ lymphocytes except for the FoxP3 histogram where all CD4+ cells
within the lymphocyte gate are shown with the mean fluorescence intensities (MFI) of
FoxP3 in the bar diagram. B. RT-PCR for TGFβ, IL10, EBI3 and GzB on flow sorted Treg
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of the dLN of FoxP3-GFP mice one and five days after degranulation. In every experiment
mice were pooled in order to get sufficient numbers of Treg. Mean and SEM are calculated
from triplicate wells.
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